Skip to main content
MedPathMedPath Home
Clinical Trials/NCT06533670
NCT06533670
Active, not recruiting
Not Applicable

Tumor Microenvironment Alteration During Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer Patients

Seoul National University Hospital1 site in 1 country30 target enrollmentJuly 19, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBreast CancerHER2-positive Breast CancerChemotherapy Effect

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Seoul National University Hospital
Enrollment
30
Locations
1
Primary Endpoint
tumor microenvironment alteration
Status
Active, not recruiting
Last Updated
3 months ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Evaluate for changes in the tumor microenvironment before/during neoadjuvant chemotherapy and after treatment in patients diagnosed with HER2-positive advanced breast cancer and receiving neoadjuvant cancer therapy and surgery for curative purposes.

Registry
clinicaltrials.gov
Start Date
July 19, 2024
End Date
July 19, 2026
Last Updated
3 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Wonshik Han

Professor

Seoul National University Hospital

Eligibility Criteria

Inclusion Criteria

  • •i. Adult patients over 18 years of age ii. Patients undergoing curative treatment including neoadjuvant chemotherapy after confirmation of breast cancer without distant metastases iii. Clinical T stage II-IV patients iv. HER2 positive breast cancer patients

Exclusion Criteria

  • •If you have other comorbidities that, according to the researcher's judgment, may affect the results of the study

Outcomes

Primary Outcomes

tumor microenvironment alteration

Time Frame: 6 months

tumor microenvironment changes during neoadjuvant chemotherapy (NAC) for HER2-positive breast cancer.

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Not Applicable
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast CancerTriple Negative Breast CancerNeoadjuvant ChemotherapyPembrolizumabTumor Microenvironment
NCT05910710Samsung Medical Center50
Recruiting
Not Applicable
Monitoring Response to Neoadjuvant Chemotherapy in Breast Cancer Using Ultrafast DCE-MRIBreast Cancer
NCT05744518Fudan University80
Completed
Phase 2
Phase II Trial for Large ER-Negative Breast CancersMalignant Neoplasm of Female Breast
NCT01869192University of Colorado, Denver72
Active, not recruiting
Not Applicable
Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast CancerInvasive Breast Carcinoma
NCT04897009Mayo Clinic38
Completed
Phase 2
Chemotherapy followed by radiotherapy response assessment in muscle invasive urinary bladder carcinomaHealth Condition 1: null- healthy
CTRI/2017/08/009318ONE20